Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13880
Country/Region: Uganda
Year: 2015
Main Partner: Makerere University
Main Partner Program: School of Public Health
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $4,170,833 Additional Pipeline Funding: $768,170

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $529,385
Care: TB/HIV (HVTB) $108,215
Care: Pediatric Care and Support (PDCS) $236,460
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $907,071
Testing: HIV Testing and Counseling (HVCT) $93,226
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,458,792
Treatment: Adult Treatment (HTXS) $782,968
Treatment: Pediatric Treatment (PDTX) $54,716
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 5,287
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 1,295
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 532
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 137
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 10,308
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 2,543
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 638
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 156
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 16,765
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,131
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 16,765
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 4,131
CARE_NEW Aggregated Age/sex: <15 Female 2016 21
CARE_NEW Aggregated Age/sex: <15 Male 2016 20
CARE_NEW Aggregated Age/sex: 15+ Female 2016 345
CARE_NEW Aggregated Age/sex: 15+ Male 2016 176
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 562
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 562
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 562
FN_THER Aggregated Age: <18 2016 40
FN_THER Aggregated Age: 18+ 2016 57
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 97
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 1,238
FN_THER Sum of Aggregated Age disaggregates 2016 97
HRH_PRE By Graduates: Other 2016 59
HRH_PRE Sum of Graduates disaggregates 2016 59
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 2,977
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 2,249
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,291
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 22,628
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 13,014
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 16,324
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 9,386
HTS_TST By Test Result: Negative 2016 42,900
HTS_TST By Test Result: Negative 2016 24,675
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 44,178
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 25,403
HTS_TST Sum of Aggregated Age/Sex <15 2016 5,226
HTS_TST Sum of Aggregated Age/Sex <15 2016 3,003
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 38,952
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 22,400
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 44,178
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 25,403
HTS_TST Sum of Test Result disaggregates 2016 44,178
HTS_TST Sum of Test Result disaggregates 2016 25,403
HTS_TST_POS By Test Result: Positive 2016 1,278
HTS_TST_POS By Test Result: Positive 2016 728
LAB_CAP By clinical laboratories 2016 1
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 1
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 3,172
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 329
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 3,172
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 329
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,855
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 296
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 317
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 33
PMTCT_ARV Sum of New and Current disaggregates 2016 3,172
PMTCT_ARV Sum of New and Current disaggregates 2016 329
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 27
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 264
PMTCT_EID Sum of Infant Age disaggregates 2016 264
PMTCT_STAT By: Known positives at entry 2016 296
PMTCT_STAT By: Number of new positives identified 2016 33
PMTCT_STAT Number of new ANC and L&D clients 2016 2,274
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 2,161
PMTCT_STAT Sum of Positives Status disaggregates 2016 329
PP_PREV Age/sex: 10-14 Female 2016 1,046
PP_PREV Age/sex: 10-14 Male 2016 818
PP_PREV Age/sex: 15-19 Female 2016 2,180
PP_PREV Age/sex: 15-19 Female 2016 213
PP_PREV Age/sex: 15-19 Male 2016 3,165
PP_PREV Age/sex: 15-19 Male 2016 191
PP_PREV Age/sex: 20-24 Female 2016 3,215
PP_PREV Age/sex: 20-24 Female 2016 268
PP_PREV Age/sex: 20-24 Male 2016 4,538
PP_PREV Age/sex: 20-24 Male 2016 212
PP_PREV Age/sex: 25-49 Female 2016 4,622
PP_PREV Age/sex: 25-49 Female 2016 339
PP_PREV Age/sex: 25-49 Male 2016 5,829
PP_PREV Age/sex: 25-49 Male 2016 327
PP_PREV Age/sex: 50+ Female 2016 308
PP_PREV Age/sex: 50+ Female 2016 114
PP_PREV Age/sex: 50+ Male 2016 91
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 26,051
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 1,755
PP_PREV Sum of Age/Sex disaggregates 2016 26,051
PP_PREV Sum of Age/Sex disaggregates 2016 1,755
PP_PREV Total number of people in the target population 2016 1,755
TB_ART Aggregated Age: <15 2016 2
TB_ART Aggregated Age: 15+ 2016 23
TB_ART Female 2016 17
TB_ART Male 2016 8
TB_ART Sum of Aggregated Age disaggregates 2016 25
TB_ART Sum of Sex disaggregates 2016 25
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 35
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 25
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 291
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 3,840
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 16,765
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 4,131
TB_SCREEN Sex: Female 2016 2,696
TB_SCREEN Sex: Male 2016 1,435
TB_SCREEN Sum of Aggregated Age disaggregates 2016 4,131
TB_SCREEN Sum of Sex disaggregates 2016 4,131
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 4,131
TX_CURR Aggregated Age/Sex: 15+ Female 2016 4,661
TX_CURR Aggregated Age/Sex: 15+ Female 2016 1,114
TX_CURR Aggregated Age/Sex: 15+ Male 2016 10,121
TX_CURR Aggregated Age/Sex: 15+ Male 2016 2,428
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 15,959
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 3,822
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 14,782
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 3,542
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 14,782
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 3,542
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 283
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 597
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 920
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 880
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 526
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 615
Cross Cutting Budget Categories and Known Amounts Total: $830,000
Renovation $90,000
Motor Vehicles: Purchased $215,000
Gender: Gender Based Violence (GBV) $250,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Gender: Gender Equality $125,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Key Populations: Sex Workers $150,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention